Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.

× No keyword cloud information.

14 in total

1. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging.

Authors: Fabricio Montalvao; Zacarias Garcia; Susanna Celli; Béatrice Breart; Jacques Deguine; Nico Van Rooijen; Philippe Bousso
Journal: J Clin Invest Date: 2013-11-01 Impact factor: 14.808

2. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Authors: Rachel Thijssen; Erik Slinger; Katinka Weller; Christian R Geest; Tim Beaumont; Marinus H J van Oers; Arnon P Kater; Eric Eldering
Journal: Haematologica Date: 2015-05-08 Impact factor: 9.941

3. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Authors: Paolo Ghia; Giuliana Strola; Luisa Granziero; Massimo Geuna; Giuseppe Guida; Federica Sallusto; Nancy Ruffing; Licia Montagna; Paola Piccoli; Marco Chilosi; Federico Caligaris-Cappio
Journal: Eur J Immunol Date: 2002-05 Impact factor: 5.532

4. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.

Authors: Ana Colado; María Belén Almejún; Enrique Podaza; Denise Risnik; Carmen Stanganelli; Esteban Enrique Elías; Patricia Dos Santos; Irma Slavutsky; Horacio Fernández Grecco; María Cabrejo; Raimundo Fernando Bezares; Mirta Giordano; Romina Gamberale; Mercedes Borge
Journal: Cancer Immunol Immunother Date: 2016-12-23 Impact factor: 6.968

5. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.

Authors: Kamil Bojarczuk; Binu K Sasi; Stefania Gobessi; Idanna Innocenti; Gabriele Pozzato; Luca Laurenti; Dimitar G Efremov
Journal: Blood Date: 2016-04-19 Impact factor: 22.113

6. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors: Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal: Blood Date: 2016-06-13 Impact factor: 22.113

7. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia.

Authors: G Pizzolo; M Chilosi; A Ambrosetti; G Semenzato; L Fiore-Donati; G Perona
Journal: Blood Date: 1983-12 Impact factor: 22.113

8. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums.

Authors: Kodi S Ravichandran
Journal: J Exp Med Date: 2010-08-30 Impact factor: 14.307

Review 9. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib.

Authors: Jeff Sharman; Julie Di Paolo
Journal: Ther Adv Hematol Date: 2016-03-17

10. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors: Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal: J Exp Med Date: 2004-06-21 Impact factor: 14.307

7 in total

1. Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.

Authors: Jonas Elias Schweig; Hailan Yao; Kyle Coppola; Chao Jin; Fiona Crawford; Michael Mullan; Daniel Paris
Journal: J Biol Chem Date: 2019-07-19 Impact factor: 5.157

2. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.

Authors: Esteban Enrique Elias; Valeria Judith Sarapura Martinez; Mikele Amondarain; Ana Colado; Gregorio Cordini; Raimundo Fernando Bezares; Horacio Fernandez Grecco; Maria Del Rosario Custidiano; Julio César Sánchez Ávalos; Gonzalo Garate; Miguel A Pavlovsky; Mercedes Borge; Mirta Giordano; Romina Gamberale
Journal: Cancer Immunol Immunother Date: 2021-08-31 Impact factor: 6.968

Review 3. In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors: Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal: Cancers (Basel) Date: 2022-06-23 Impact factor: 6.575

Review 4. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Authors: Carlos Cuesta-Mateos; Jennifer R Brown; Fernando Terrón; Cecilia Muñoz-Calleja
Journal: Front Immunol Date: 2021-03-24 Impact factor: 7.561

Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.